Is Ruxolitinib tablets on the market?

Ruxolitinib was first approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of adult patients with myelofibrosis. It was subsequently approved by the European Union in 2012. Ruxolitinib is sold under the trade names Jakafi and Jakavi. In 2014, ruxolitinib tablets were approved for the treatment of polycythemia vera in adults with an inadequate response to or intolerance to hydroxyurea. In 2019, Ruxolitinib tablets were approved for the treatment of steroid-refractory acute graft-versus-host disease in adults and children.

Myelofibrosis(MF) is a myeloproliferative neoplasm that can manifest as a new disease such as primary myelofibrosis(PMF), or secondary to polycythemia vera (PV) or essential thrombocythemia (ET). AndRuxolitinib tablets are an anti-tumor drug that can inhibit cell proliferation, induce malignant cell apoptosis, and reduce plasma levels of pro-inflammatory cytokines by inhibiting JAK-induced phosphorylation of signal transducers and activators of transcription (STAT).

Ruxolitinib tabletsThe original drug has been launched in China and is included in the scope of Class B medical insurance. It is limited to patients who meet the indications. Specification The price of each box of 5mg*60 tablets may be around RMB 3,000. The Turkish version of ruxolitinib tablets listed overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.